Neoadjuvant TACE With or Without RT for HCC Involving PVTT

• Status: Active, not recruiting
• Trial end date: 2021-12-31
• Target enrollment: 214
• Participant gender: All

Summary

The rate of patients with hepatocellular carcinoma (HCC) involving portal vein tumor thrombus (PVTT) is up to 50% in Guangxi province, China. Some of them will receive hepatic resection. However, 5-years recurrence rate is up to 75%. Some retrospective studies found transarterial chemoembolization or radiotherapy can downstage HCC.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Guangxi Medical University

Criteria

Inclusion Criteria:

• Age 18-75 years;

• Patients with resectable primary hepatocellular carcinoma and Cheng's type II/III portal vein tumor thrombus (ie, PVTT that involved the right- or left-side branch or main trunk of the portal vein);

• Child-Pugh A or B (7 score) liver function;

• With more than 3 months expected survival;

• The volume of residual liver more than 30%;

• Patients agree to take part in.

Exclusion Criteria:

• Previous history of epigastric radiotherapy

• With extrahepatic metastasis

• With TACE or radiotherapy contraindication;

• Pregnant woman or sucking period;

• With repture tumor;

• With other cancer in previous five years;

• With chemothrapy, target therapy or immunosuppressive drugs therapy.